Clinical Trial Search

Primary: Percentage of Participants Who Develop Anti-GH Antibodies After Treatment With Nutropin AQ v1.1 — 3.7 percentage of participants

Primary: Height Velocity From Pretreatment (Week 0) to Week 34 — 7.0 centimeters per year (cm/yr)

Primary: Change in Insulin Sensitivity — 0.20; 1.44; -0.63; 0.14 uU*10^-4*min*ml^-1

Primary: Height Velocity During the First Year - Intent to Treat (ITT)Population — 5.2; 6.9; 7.7 cm/yr — p=<0.0001

Primary: Height Standard Deviation Score — -2.52; -1.57; -1.19; -1.09 standard deviation score

Primary: Number of Participants With Treatment Related Adverse Events. — 29 participants

Primary: Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan — -1.7 kg — p=<0.001

Primary: Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug — 0.23; 0.07; 1.24 ng/mL — p=0.01

Primary: Functional Outcome 6 Months After Injury, as Measured by the Processing Speed Index — 82.5; 82.5 Processing speed index standardized scor

Primary: Height Velocity (Ht-V) — 12.02; 6.87 cm/year — p=<0.0001

Primary: Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire — 29.5; 27.1 units on a scale

Primary: Percentage of Participants With Less Than 11 Tender Points at Month 6 — 20; 22 Percentage of participants

Primary: Annualized Height Velocity at 52 Weeks for Weekly Lonapegsomatropin and Daily hGH Treatment Groups — 11.17; 10.31 cm/year — p=0.0088

Primary: Annualized Height Velocity Up to 12 Years — 2.6; 8.0; 5.9; 5.5 centimeter per year (cm/y)

Primary: Height SDS at Year 4 — -1.35; -2.44 standard deviation score

Primary: Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years — -2.9488; -2.9047; 1.2066; 2.0247…

Primary: Annual Height Velocity — 9.43; 10.70 cm/year

Primary: Change in Truncal Fat Percentage (Week 34) — 0.49; -2.39; -1.17 Percentage of truncal fat — p==0.0090

Primary: Incidence of Anti-hGH Binding Antibody Formation — 1; 0; 0; 0 participants

Primary: Annualized Height Velocity(cm/Year) After 26 Weeks — 10.68; 5.72 cm/year

Primary: The Number of Patients Who Achieve a Trough Human Growth Hormone (hGH) Concentration of <2.5µg/L During the Last 12 Hours of the 23 Hour Profile Following Each Study…

Primary: Crohn's Disease Histologic Index of Severity (CDHIS) — 7; 8; 6; 8 scores on a scale

Primary: Number of Participants With Development of Diabetes in Short Children Born SGA During Treatment — 0 Participants

Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049

Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] — 83; 6; 1; 0 Participants

Primary: Number of Subjects Reporting Local Tolerability Events (Assessed by the Patient and Investigator) — 3; 3; 2; 1 Number of subjects with any symptom

Primary: Mean Overnight Growth Hormone — 1.2 mcg/L — p=<0.005

Primary: Height Velocity — 6.40; 4.40 centimeter (cm)/year — p=0.001

Primary: Peak VO2 — 14.5; 12.9 ml/kg/min

Primary: Number of Participants Who Died — 14; 96; 4; 7 participants